Market News AIOpen the app

Plus Therapeutics shared news about finishing a Phase 2 trial and details on its cash and funding.

TrialRead the original at Business Insider
Neutral

Cerenome finished Phase 2 enrollment, and 10 repeat-dose patients had no dose-limiting toxicities or side-effect-related treatment stops. The report gives no treatment-benefit results and lists $4.9 million in cash, a $20 million secured financing facility, and $3.8 million raised through share sales, leaving a mixed picture.

CNSY · Cerenome, Inc.

AI read · Neutral

The AI's read

The trial has moved ahead, and early safety results give Cerenome a reason to keep testing REYOBIQ. The report gives safety findings, not proof that the treatment helps patients. The company also reported cash, secured financing, and money raised through share sales, leaving the update without a clear direction.

Get alerts for CNSY

Follow Cerenome, Inc. (CNSY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CNSY
Free on the App Store and Google Play, or on the web.